Tryp Therapeutics Valuation
Based on Macroaxis valuation methodology, the company cannot be evaluated at this time. Tryp Therapeutics current Real Value cannot be determined due to lack of data. The regular price of Tryp Therapeutics is $0.0. Our model measures the value of Tryp Therapeutics from inspecting the company fundamentals such as Return On Equity of -9.22, shares outstanding of 96.42 M, and Shares Owned By Institutions of 0.04 % as well as reviewing its technical indicators and probability of bankruptcy. . In general, most investors recommend locking in undervalued stocks and disposing overvalued stocks since, at some point, asset prices and their ongoing real values will draw towards each other.
Tryp Therapeutics Total Value Analysis
Tryp Therapeutics is at this time projected to have takeover price of 4.17 M with market capitalization of 6.56 M, debt of , and cash on hands of 2.85 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Tryp Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.17 M | 6.56 M | 2.85 M |
Tryp Therapeutics Asset Utilization
One of the ways to look at asset utilization of Tryp is to check how much profit was generated for every dollar of assets it reports. Tryp Therapeutics has a negative utilization of assets of -2.05 %, losing $0.0205 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Tryp Therapeutics shows how discouraging it operates for each dollar spent on its assets.Tryp Therapeutics Ownership Allocation
Tryp Therapeutics shows a total of 96.42 Million outstanding shares. Tryp Therapeutics maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Tryp Therapeutics Profitability Analysis
Net Loss for the year was (7.49 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Tryp Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Tryp Therapeutics and how it compares across the competition.
Tryp Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Tryp Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 96.4 M | |
| Retained Earnings | -16.2 M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Tryp OTC Stock
If you are still planning to invest in Tryp Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tryp Therapeutics' history and understand the potential risks before investing.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |